{"title": "Diabetische Retinopathie", "author": null, "url": null, "hostname": null, "description": "Non-proliferative diabetic retinopathy treated with runcaciguat...", "sitename": "Bayer \u2013 Clinical Trials Explorer", "date": "2019-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Trial Condition(s):\nNon-proliferative diabetic retinopathy treated with runcaciguat (NEON-NPDR)\n20739\nNot Available\nDiese Phase-2-Studie wird durchgef\u00fchrt, um die Sicherheit und Wirksamkeit von Runcaciguat bei der Behandlung der diabetischen Retinopathie zu untersuchen. Um die Wirksamkeit zu beurteilen, wird die Netzhautmorphologie durch die 7-Feld-Farbfundusfotografie zur zentralen Beurteilung des Schweregrads der diabetischen Retinopathie (Diabetic Retinopathy Severity Score, DRSS) untersucht. Die zweistufige DRSS-Verbesserung nach 24 Behandlungswochen ist der prim\u00e4re Wirksamkeitsendpunkt. Die DRSS-Bewertungen werden nach Abschluss von 48 Wochen Behandlung wiederholt. Dar\u00fcber hinaus werden visusbedrohende Komplikationen w\u00e4hrend der gesamten Studie aufgezeichnet und als sekund\u00e4rer Wirksamkeitsendpunkt bewertet.\n- Moderately severe to severe NPDR in the study eye: Diabetic Retinopathy Severity Scale (DRSS) levels 47 or 53 - Diabetes type 1 or 2 - Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye of \u226569 letters (approximate Snellen equivalent of 20/40 or better) Main\n- Presence or history of macular edema involving the center of the macula - Any kind of neovascular growth in the study eye, including anterior segment neovascularization - Arterial hypotension with systolic blood pressure < 100 or diastolic blood pressure < 60mmHg - Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) above 3 x Upper limit of normal (ULN) or bilirubin \u2265 1.5 ULN at screening, known ascites - Estimated glomerular filtration rate (eGFR CKD-EPI) below 30 ml/min/1.73 m^2 at screening - Any prior systemic anti-Vascular endothelial growth factor (VEGF) treatment or IVT anti-VEGF treatment in the study eye - Any prior intraocular steroid injection in the study eye - Any prior grid or focal laser photocoagulation within 500 microns of the foveal center or any prior Pan-retinal photocoagulation (PRP) in the study eye - Use of nitrates or Nitric oxide (NO) donors (such as amyl nitrate) in any form including topical; Phosphodiesterase 5 (PDE5) inhibitors, nonspecific PDE inhibitors within 1 week or less than 5 half-lives (whichever is longer) before first study drug administration\n|Studienstandorte|\nStudienstandorte\nNUVISAN GmbH Neu-Ulm\nNeu-Ulm, Germany, 89231\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nOdense Universitetshospital, Dept of Ophtalmology\nOdense C, Denmark, 5000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSj\u00e6llands Universitetshospital Roskilde\nRoskilde, Denmark, 4000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nGlostrup Hospital\nGlostrup, Denmark, 2600\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nAalborg Universitetshospital, Ophtalmology dept.\nAalborg, Denmark, 9000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nAarhus Universitetshospital, Skejby\nAarhus N, Denmark, 8200\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nBiokinetica S.A\nJozefow, Poland, 05-410\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nNZOZ Centrum Badan Klinicznych\nWroclaw, Poland, 51-162\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nCHUC - Hospitais da U. Coimbra - Servico de Oftalmologia\nCoimbra, Portugal, 3004-561\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nCentro Hospitalar Universitario do Porto\nPorto, Portugal, 4099-001\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nGloucester Royal Infirmary\nGloucester, United Kingdom, GL1 3NN\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSunderland Eye Infirmary\nSunderland, United Kingdom, SR29HP\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMoorfields Eye Hospital\nLondon, United Kingdom, EC1V2PD\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nBristol Eye Hospital\nBristol, United Kingdom, BS12LX\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nVseobecna fakultni nemocnice v Praze\nPraha 2, Czech Republic, 12808\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nFakultni nemocnice Kralovske Vinohrady\nPraha 10, Czech Republic, 100 34\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nUniversity Eye Hospital Jules Gonin\nLausanne, Switzerland, 1004\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nKing's College Hospital - NHS Foundation Trust\nLondon, United Kingdom, SE5 9RS\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nAXON Clinical s.r.o.\nPraha 5, Czech Republic, 150 00\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nAcademic Medical Center Dept Ophthalmology\nAmsterdam, Netherlands, 1100 DD\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nUniversitair Medisch Centrum St. Radboud\nNIJMEGEN, Netherlands\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nETZ Elisabeth Ziekenhuis\nTilburg, Netherlands, 5022 GC\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nHospital Universitario Virgen de la Macarena\nSevilla, Spain, 41071\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nCiutat Sanitaria i Universitaria de la Vall d'Hebron\nBarcelona, Spain, 08035\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nHospital General de Catalunya\nSant Cugat del Vall\u00e9s, Spain, 08195\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nHospital Universitario de Henares\nCoslada, Spain, 28822\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nAIBILI\nCoimbra, Portugal, 3000-548\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nCHUSJ - Hospital Sao Joao\nPorto, Portugal, 4200-319\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nKlinika Okulistyczna \"Jasne Blonia\" Sp. z o.o\nLodz, Poland, 91-134\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nInd. Spec. Prakt. Lek. Dr W. Jedrzejewski\nTarnowskie Gory, Poland, 42-600\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nNemocnica Poprad, a.s.\nPoprad, Slovakia, 058 45\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nFakultna Nemocnica s poliklinikou F.D.Roosevelta\nBanska Bystrica, Slovakia, 97517\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nGulf Coast Institute / Valley Retina Institute\nMcAllen, United States, 78503\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nFlorida Retina Consultants\nLakeland, United States, 33805-2908\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nAustin Research Center for Retina\nAustin, United States, 78705-1023\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nRetina Consultants of Houston\nThe Woodlands, United States, 77384\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nRiga East Clinical University Hospital \"Gailezers\"\nRiga, Latvia, LV-1006\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nClinical Emergency County Hospital\nCluj-Napoca, Romania, 400006\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nOcni klinika Oftex\nPardubice, Czech Republic, 530 02\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nUMHAT Sveti Georgi\nPlovdiv, Bulgaria, 4000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nEye center Sveti Luka\nPlovdiv, Bulgaria, 4001\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSveta Petka Eye Hospital\nVarna, Bulgaria, 9002\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSEHAT Pentagram\nSofia, Bulgaria, 1309\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nCumberland Valley Retina Consultants, PC\nHagerstown, United States, 21740-5940\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nRetinal Consultants of Texas - San Antonio\nSan Antonio, United States, 78240\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nAustin Retina Associates\nAustin, United States, 78705\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nRetinal Consultants Medical Group, Inc\nSacramento, United States, 95825\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nEye Associates of Pinellas\nPinellas Park, United States, 33782\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMid Atlantic Retina Specialists\nHagerstown, United States, 21740\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nRetinal Consultants of Texas - San Antonio\nBellaire, United States, 77401\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nA Phase 2 randomized, placebo-controlled, double-masked proof-of-concept study to investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately severe to severe non-proliferative diabetic retinopathy\nTrial Type:\nInterventional\nIntervention Type:\nDrug\nTrial Purpose:\nTreatment\nAllocation:\nRandomized\nBlinding:\nN/A\nAssignment:\nParallel Assignment\nTrial Arms:\n2", "language": null, "image": "https://clinicaltrials.bayer.com/images/clinical_trials_explorer_logo.png", "pagetype": "website", "links": ["/", "/why-participate", "/#enhancingDiversity", "/what-are-clinical-trials", "/what-to-expect", "/transparency-policy", "https://www.facebook.com/sharer/sharer.php?u=", "https://twitter.com/share?url=", "https://www.linkedin.com/shareArticle?mini=true&url=", "/cdn-cgi/l/email-protection#dde2aea8bfb7b8bea9e09fbca4b8affdaea9a8b9a4fdb2b3fd99b4bcbfb8a9b4befdafb8a9b4b3bcb1fdb9b4aeb2afb9b8affbbcb0ade6bfb2b9a4e094fdb7a8aea9fdbbb2a8b3b9fda9b5bca9fd9fbca4b8affdb5bcaefdbcfdaea9a8b9a4fdbbb2affdadb8b2adb1b8fdaab4a9b5fd99b4bcbfb8a9b4befdafb8a9b4b3bcb1fdb9b4aeb2afb9b8aff8ed99f8ed9c84b2a8fdbebcb3fdb1b8bcafb3fdb0b2afb8fdbfa4fdbeb1b4beb6b4b3bafdb2b3fda9b5b8fdb1b4b3b6fdbfb8b1b2aaf3fd", "https://clinicaltrials.gov/ct2/show/?term=NCT04722991&rank=1", "https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002333-15", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "https://www.facebook.com/pharma.bayer/", "https://twitter.com/bayerpharma", "https://www.youtube.com/bayerpharma", "/terms-use", "/privacy-statement", "/contact-us", "/transparency-policy", "/sitemap"]}